文献速递慢性静脉疾病静脉血栓栓塞

INSIGHTS-SVT研究的基本原理、设计与方法:浅静脉血栓患者诊疗现状与结局的前瞻性观察研究

Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2017-01-01

INSIGHTS-SVT是一项在德国开展的前瞻性观察研究,计划纳入约1200例超声确诊的急性孤立性下肢浅静脉血栓患者,由多达120名常规诊治SVT且能进行压缩超声诊断的医生参与。研究不规定干预措施,在基线和约3个月评估主要疗效结局(静脉血栓栓塞发生率)和主要安全性结局(大出血与临床相关出血的复合发生率),旨在反映真实临床实践中的治疗路径与结局。

要点

  • 研究聚焦超声确诊的急性孤立性下肢浅静脉血栓患者,计划样本约1200例。
  • 主要疗效结局为3个月静脉血栓栓塞发生率,主要安全结局为3个月大出血与临床相关出血复合发生率。
  • 研究不规定干预措施,旨在收集真实临床实践中的治疗选择、药物使用与结局数据。

核心结论

  • 该大型研究预期将全面呈现德国临床实践条件下浅静脉血栓患者的诊疗现状与结局。

研究设计与样本

  • 前瞻性观察研究,计划纳入约1200例超声确诊的急性孤立性下肢浅静脉血栓患者。
  • 由多达120名常规诊治SVT并能进行压缩超声诊断的临床和诊所医生参与,包括血管医生、静脉学医生、内科医生、血管外科医生和全科医生。
  • 不规定干预措施,在基线、10±3天或约45天(取决于治疗)、约3个月和约12个月收集患者特征、诊断、合并症及药物和非药物治疗信息。
  • 患者在基线和约3个月填写疼痛、VEINES-QOL/Sym和EQ-5D-5L生活质量问卷。

关键数值与推荐

  • 主要疗效结局为3个月静脉血栓栓塞发生率。
  • 主要安全性结局为3个月大出血和临床相关出血事件的复合发生率。
  • 质量措施包括数据录入时的合理性检查、基于统计分析的异常值和数值分布查询、监查访视以及裁定程序。

临床怎么用

  • 研究结果可为临床医生选择浅静脉血栓患者的治疗策略和评估预后提供真实世界参考。
  • 通过收集治疗路径、药物使用和结局数据,有助于识别当前实践中需优化的环节。

局限性

  • 研究为观察性设计,不规定干预措施,结果可能受混杂因素影响。
  • 研究在德国开展,结论外推至其他医疗体系时需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Superficial vein thrombosis (SVT) is a common disease in clinical practice. In terms of pathophysiology and outcomes, the condition is related to venous thromboembolism, bearing a potential for severe thromboembolic complications if it is not treated adequately. A wide range of treatment approaches (including oral and injectable anticoagulants, pain medication, nondrug therapy including compression therapy, and no treatment at all) are applied in clinical practice, but there is sparse information about selection of patients for therapies, current treatment pathways, and drug use as well as outcomes. The INvestigating SIGnificant Health TrendS in the management of Superficial Vein Thrombosis (INSIGHTS-SVT) study aims to close this gap by collecting representative data on the current treatment of SVT. METHODS: The observational prospective study of about 1200 patients is carried out by up to 120 clinical and office-based physicians who regularly treat patients with SVT and are capable of conducting appropriate compression ultrasound diagnostics, such as vascular physicians, phlebologists, internists, vascular surgeons, and general practitioners. Patients are eligible for inclusion if they have ultrasound-confirmed acute, isolated SVT of the lower extremities. Documentation about the characteristics of the patients, diagnostics, comorbidities, and medical and nonmedical treatment is collected at baseline, at 10 ± 3 days or at approximately 45 days (depending on treatment), at approximately 3 months, and at approximately 12 months. Patients are requested to fill in quality of life questionnaires (on pain, Venous Insufficiency Epidemiological and Economic Study on Quality of Life/Symptoms [VEINES-QOL/Sym], EuroQol-5 Dimension 5-Level [EQ-5D-5L]) at baseline and at approximately 3 months. Interventions are not stipulated by the trial protocol. RESULTS: The primary efficacy outcome is the incidence of venous thromboembolism at 3 months; the primary safety outcome is the combined incidence of major and clinically relevant bleeding events at 3 months. As quality measures, plausibility checks at data entry, queries based on statistical analyses that focus on outliers and distribution of values, monitoring visits, and adjudication procedures will be applied. CONCLUSIONS: This large study is expected to provide a comprehensive picture of patients with SVT under clinical practice conditions in Germany.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Bauersachs R, Gerlach HE, Heinken A, et al. Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2017. PMID: 28623995. doi:10.1016/j.jvsv.2017.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。